Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations

Next Previous
Trial Profile

Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 08 Sep 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
  • 15 Jul 2015 According to the ClinicalTrials.gov record, planned number of patients changed from 48 to 81.
  • 06 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top